SEGG Media Congratulates Lando Norris on 2025 Formula 1 World Championship

Rhea-AI Summary

IceCure Medical (Nasdaq: ICCM) presented ProSense® liquid-nitrogen single‑probe cryoablation data and training at CIRSE 2025 in Barcelona, highlighting independent clinical studies and hands‑on sessions for interventional radiologists.

Key items: PRECICE will treat 234 Luminal A/B patients >50; a prospective series reported outcomes for 55 elderly HR+/HER2- patients (median age 86); a cohort of 39 inoperable malignant lesions showed efficacy in small, low‑grade HR+ unifocal IDC; an AWE study reported pain scores falling from 8 to 1 and MRI necrosis/resolution in 95% of cases.

Positive

• PRECICE trial: 234 Luminal A/B patients enrolled using ProSense®
• Prospective study: 55 elderly HR+/HER2- patients treated with cryoablation
• AWE study: pain scores decreased from 8 to 1
• AWE MRI response: necrosis/resolution in 95% of cases
• Focused CIRSE sessions and 3 hands-on trainings increased clinician engagement

Negative

• Several clinical reports are small cohorts: 55 and 39 patients
• Primary positive findings limited to HR+ HER2- and unifocal small tumors
• PRECICE is investigator-led and sponsored externally, not a completed regulatory study

Key Figures

Breast cancer patients 234 patients PRECICE independent study using ProSense for Luminal A/B >50 years

Mean age (non-surgical cohort) 83.4 years Breast cancer patients ineligible for surgery in comparative HT/cryoablation study

Prospective cohort size 55 patients First patients treated with cryoablation at Institut Curie

Median age (Institut Curie study) 86 years Elderly patients with small HR+/HER2- breast cancers

Breast lesions assessed 39 malignant lesions Inoperable B5 lesions evaluated one year after cryoablation

Pain score reduction 8 to 1 (scale 1–10) Abdominal wall endometriosis treated with percutaneous cryoablation

MRI response rate 95% of cases AWE lesions showing necrosis and resolution of hemorrhagic signals

CIRSE meeting dates September 13–17, 2025 Conference where ProSense cryoablation data and trainings were presented

Market Reality Check

$1.33 Last Close

Volume Today’s volume of 146,627 is below the 20-day average of 233,199, suggesting muted trading interest. low

Technical Shares at $1.33 are trading below the 200-day MA of $5.88 and far below the 52-week high of $13.70.

Peers on Argus

SEGG fell 6.99% while key peers were mixed: ROLR up 15.62%, LTRY up 7.87%, GAMB up 3.39%, BRAG down 0.45%, and JKPTF flat. The move appears stock-specific rather than a sector-wide shift.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 01	Leadership change	Positive	-6.1%	Board removed prior CEO and elevated interim leadership to drive growth and discipline.
Nov 25	Platform growth update	Positive	-4.9%	Company surpassed 102 million views and reiterated expansion and acquisition plans.
Nov 20	Content acquisition	Positive	-8.2%	Agreement to acquire 51% of Ant Media & Productions and secure streaming rights.
Nov 13	Ad-tech acquisition LOI	Positive	-7.5%	Binding LOI to buy Triggy.AI to add AI-driven ad monetization capabilities.
Nov 12	Marketing expansion	Positive	-14.6%	Sports.com brand expansion via NBA yearbook advertising across major U.S. markets.

Pattern Detected

Recent SEGG headlines describing expansion, acquisitions, and leadership changes were followed by consistent share price declines, indicating a pattern of negative reactions to ostensibly strategic or growth-focused news.

Recent Company History

Over the past month, SEGG issued multiple growth-oriented updates, including NBA advertising expansion on Nov 12, an LOI to acquire Triggy.AI on Nov 13, and a 51% stake agreement for Ant Media & Productions on Nov 20. The company also highlighted surpassing 102 million views on Nov 25 and leadership changes on Dec 1. Despite these announcements, each event coincided with negative next-day price reactions, framing today’s decline against a backdrop of persistent skepticism.

Market Pulse Summary

This announcement centers on favorable clinical data and strong physician engagement around ProSense cryoablation, including studies in early-stage breast cancer and abdominal wall endometriosis where pain scores fell from 8 to 1 and MRI changes occurred in 95% of cases. In SEGG’s broader context, recent regulatory filings noted ongoing losses and going-concern language, so investors may monitor how such medical-technology headlines relate (if at all) to SEGG’s core media and gaming strategy.

Key Terms

cryoablation medical

"developer of minimally-invasive cryoablation technology that destroys tumors by freezing"

A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.

interventional radiologists medical

"growing number of interventional radiologists looking to grow their practice in breast care"

Interventional radiologists are doctors who use medical imaging (like X‑rays, CT scans, or ultrasound) as a live “GPS” to guide thin instruments and small needles to treat conditions without open surgery. For investors, they matter because their techniques drive demand for specialized imaging machines, disposable devices and new minimally invasive therapies, influence hospital procedure mix and reimbursement trends, and can shorten recovery times that affect healthcare costs and patient volumes.

lumpectomy medical

"from radical surgery, through lumpectomy, to current treatment alternatives"

A lumpectomy is a surgical procedure that removes a breast tumor along with a small ring of surrounding tissue, preserving most of the breast like cutting a stain out of a shirt rather than replacing the whole garment. Investors watch lumpectomy rates and related technology because they affect demand for surgical tools, hospital services, follow-up therapies and reimbursement patterns, which in turn influence revenue and cost projections for medical device makers, hospitals and insurers.

hormonal therapy medical

"cryoablation combined with hormonal therapy ("HT") versus cryoablation alone"

Hormonal therapy is a medical treatment that changes the levels or actions of hormones in the body to slow or stop disease processes, most commonly used against hormone-sensitive cancers. Investors care because clinical results, approval decisions, patent protection and market demand for these treatments can strongly affect a company’s future revenue and stock value — think of a successful hormonal therapy as unlocking a new, steady revenue stream for a drug maker.

HER2- medical

"hormone receptor-positive (HR+) human epidermal growth factor receptor 2- negative (HER2-)"

HER2- describes a tumor that lacks an excess of the HER2 protein or the gene that produces it; HER2 is a cell-surface receptor that can fuel cancer growth when overabundant. For investors, HER2- status matters because it determines whether patients will benefit from HER2-targeted medicines — like finding there is no matching lock for a specialized key — which directly affects the size of the eligible patient pool, treatment choices, pricing dynamics and potential sales for related drugs.

invasive ductal carcinoma medical

"unifocal invasive ductal carcinoma (IDC) (the patient cohort evaluated in the study)"

A common type of breast cancer that starts in the milk ducts and has grown into the surrounding breast tissue; think of it like a weed that has spread out from its original patch. It matters to investors because its prevalence, treatment options, prognosis and regulatory pathway drive demand for diagnostics, drugs, surgeries and long‑term care, which in turn affect clinical trial outcomes, healthcare spending and the commercial value of related medical companies.

percutaneous medical

"efficacy and safety of percutaneous single probe cryoablation using liquid nitrogen"

Percutaneous describes medical procedures or delivery methods that reach internal organs or tissues by passing through the skin — for example with needles, catheters or small tubes — instead of opening the body with large incisions. For investors it matters because percutaneous approaches are generally less invasive, often mean lower hospital time, quicker recovery and smaller device footprints, which can broaden market adoption and affect regulatory and reimbursement outlooks.

MRI medical

"MRI showed necrotic changes and resolution of hemorrhagic signals in 95% of cases"

Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives demand for imaging machines, hospital services, diagnostics and can be central to clinical trial results and regulatory decisions—changes in MRI use or technology can affect revenue, capital spending and reimbursement in healthcare and medical device markets.

AI-generated analysis. Not financial advice.

Presentations from 5 Key Opinion Leaders on ProSense® cryoablation including 3 independent studies on breast cancer and 1 on endometriosis   

3 hands-on training sessions for doctors interested in using ProSense® were very well attended

Dedicated CIRSE focus session on the breast shows the growing interest from interventional radiologists to expand their practice to include care for breast cancer patients

CAESAREA, Israel, Sept. 22, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced its participation at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting on September 13-17, 2025, in Barcelona, Spain. The Company hosted a large number of medical practitioners interested in ProSense® at its booth. Booth visitors experienced live demonstrations and learned about how ProSense®, a single-cryoprobe liquid nitrogen ("LN2") based cryoablation technology is shaping the future of interventional oncology, especially for breast cancer patients.

 

 

"We had a very successful participation at CIRSE this year, as ProSense® offers what we believe is the most advanced clinically proven LN2 cryoablation system to the growing number of interventional radiologists looking to grow their practice in breast care," stated IceCure's Chief Executive Officer, Eyal Shamir. "As always, we truly appreciate the medical doctors who have conducted their own investigator-initiated studies of ProSense® and who continue to actively share their findings and positive experiences with their colleagues at these important medical conferences."

ProSense® was featured in the following:

• 3 Hands-on device trainings for cold ablation featuring ProSense® were conducted

- Honorary lecture "Breaking barriers in breast cancer - cryoablation as the ultimate expression of IO's de-escalation philosophy," delivered by Dr. Franco Orsi, Chief of Interventional Radiology, European Institute of Oncology, Milan, Italy. The lecture focused on the evolution of breast cancer treatment from radical surgery, through lumpectomy, to current treatment alternatives

- Dr. Orsi highlighted the PRECICE trial and ProSense® cryoablation system as the study's chosen technology to treat breast cancer patients

-  PRECICE, an independent study led by Dr. Orsi and the European Institute of Oncology, with sponsorship from the Italian Ministry of Health, is exclusively using ProSense® to treat 234 Luminal A and B patients >50 years of age with early-stage breast cancer, a wider population of patients than IceCure's ICE3 study

• 3 presentations on breast cancer were delivered during the Focused Therapies for Challenging Tumors session

-  Abstract Title:Comparative assessment of non-surgical treatment strategies for breast cancer: evaluating the effectiveness of cryoablation with hormonal therapy versus cryoablation alone and hormonal therapy alone in patients deemed ineligible for surgery;
   - Presenter: Dr. Sofia Baldi Giorgi, Radiology Resident, Careggi University Hospital, Florence, Italy

-  Study's Focus: To evaluate the most effective non-surgical treatment for breast cancer in patients ineligible for surgery by comparing ultrasound-guided cryoablation combined with hormonal therapy ("HT") versus cryoablation alone and HT alone; mean age 83.4 years
   - Key Findings: Cryoablation combined with HT significantly reduced mean tumor size and residual disease compared to HT alone, supporting its potential as a promising treatment for surgery-ineligible patients

- Abstract Title:Cryoablation for Small HR+ Breast Cancers in Elderly Patients: A Prospective Study of the First 55 Patients Treated at Institut Curie
   - Presenter: Dr. Toulsie Ramthohul, Interventional Radiologist, Institut Curie Hospital, Paris, France
   - Study's Focus: Prospective study that evaluated the clinical and radiological outcomes of the first 55 patients treated at Institute Curie with cryoablation as an alternative to surgery for cT1 hormone receptor-positive (HR+) human epidermal growth factor receptor 2- negative (HER2-) breast cancers in elderly patients; median age was 86 years; age range 75-94 years
   - Key Findings: Cryoablation using ProSense® is a safe and effective alternative to surgery for elderly patients with small HR+/Her2- breast cancers, even in high-risk populations

-  Abstract Title:Differential efficacy of cryoablation in breast tumor subtypes: ultrasound-guided scar biopsy evaluation one-year post-treatment
   - Presenter: Dr. Francesca Pugliese, Radiology Resident, EdiR, Breast Imaging, Careggi University Hospital, Florence, Italy
   - Study's Focus: To assess the effectiveness of cryoablation in different subtypes of breast tumors, a cohort of 39 inoperable biopsy-proven B5 (malignant) lesions underwent ultrasound-guided scar biopsy evaluations one year post-treatment
   - Key Findings: Cryoablation was found to be a safe and effective option for patients with small, low-grade hormone receptor-positive (HR+), unifocal invasive ductal carcinoma (IDC) (the patient cohort evaluated in the study), offering a potential alternative to breast-conserving surgery.

• Presentation of a study by Dr. Ghizlane Touimi Benjelloun, Chu De Nîmes, Nîmes, France on ProSense® in the treatment of abdominal wall endometriosis by

   - Presenter: Prof. Julien Frandon, Director of the Interventional Radiology Department, Nîmes University Hospital 
   - Abstract Title:Efficacy and safety of percutaneous single probe cryoablation using liquid nitrogen in treatment of abdominal wall endometriosis
   - Study's Focus: To evaluate the effectiveness and safety of percutaneous image-guided single probe cryoablation in treating symptomatic abdominal wall endometriosis ("AWE") lesions, with a focus on pain relief and treatment outcomes
   - Key Findings: Pain scores significantly decreased from a mean of 8 on a scale of 1 to 10 to a mean of 1 on a scale of 1 to 10. MRI showed necrotic changes and resolution of hemorrhagic signals in 95% of cases. Cryoablation preserved aesthetic outcomes, with no visible scars. Percutaneous cryoablation was found to be a safe and effective alternative to surgery for AWE, offering significant pain relief with minimal morbidity

About ProSense®

The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.

ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors.

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses the belief that ProSense® offers the most advanced clinically proven LN2 cryoablation system. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:

Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914

Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/icecures-prosense-featured-at-cirse-2025-annual-meeting-positive-clinical-results-with-cryoablation-from-4-independent-studies-presented-302562830.html

SOURCE IceCure Medical

FAQ

What did IceCure announce about ProSense® at CIRSE 2025 (Nasdaq: ICCM)?

IceCure showcased ProSense® with 3 hands-on trainings, focused presentations, and independent studies including PRECICE (using ProSense® for 234 patients).

What were the key breast cancer study results presented for ICCM ProSense®?

Presentations reported safety and efficacy in elderly HR+/HER2- patients (55 patient prospective series) and effective control in 39 inoperable small, low‑grade IDC lesions at one year.

How did ProSense® perform in the abdominal wall endometriosis (AWE) study presented at CIRSE 2025?

The AWE study showed mean pain scores falling from 8 to 1 and MRI evidence of necrosis/resolution in 95% of cases.

What patient populations are represented in the PRECICE trial using ProSense®?

PRECICE is enrolling 234 Luminal A and B patients aged >50 with early‑stage breast cancer.

Will ProSense® broaden interventional radiology breast care based on CIRSE findings?

CIRSE presentations and trainings indicate growing clinician interest and use of ProSense® to expand interventional breast care, especially for elderly or surgery‑ineligible patients.